This technology provides a non-invasive, spectroscopic method using Raman spectroscopy to diagnose and monitor Alzheimer’s disease by analyzing biochemical changes in blood serum.
Background: Alzheimer’s disease presents significant diagnostic challenges, often requiring invasive or costly procedures with limited early detection capabilities. Traditional diagnostic methods lack efficiency for timely and accurate identification, which is crucial for managing disease progression. Research into spectroscopic techniques revealed the potential for detecting molecular changes associated with Alzheimer’s in blood serum, leading to the development of this innovative diagnostic approach.
Technology Overview: This technology employs Raman spectroscopy, specifically including Surface Enhanced Raman Spectroscopy (SERS), to obtain a unique spectroscopic signature from a subject’s blood serum sample. By analyzing this signature, the method detects biochemical markers indicative of Alzheimer’s disease. The Raman spectroscopic signature reflects molecular vibrations that change as the disease progresses, allowing differentiation between healthy individuals, Alzheimer’s patients, and those with other types of dementia. Advanced statistical tools such as support vector machines (SVM) and artificial neural networks (ANN) are integrated to analyze the spectroscopic data. These machine learning methods classify the spectral signatures with high accuracy, enhancing diagnostic reliability. Experimentation has validated this approach’s effectiveness in identifying Alzheimer’s disease and monitoring its progression. The value proposition lies in its non-invasive nature, employing blood serum samples rather than more invasive brain imaging or cerebrospinal fluid analysis. It offers a cost-effective, rapid, and scalable tool for early diagnosis and disease monitoring, potentially transforming patient care by enabling timely therapeutic interventions.
https://suny.technologypublisher.com/files/sites/adobestock_733997563.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Non-invasive testing method using easily accessible blood serum samples. • High diagnostic accuracy facilitated by advanced machine learning classification. • Capability to distinguish Alzheimer’s disease from other forms of dementia. • Cost-effective and rapid compared to traditional imaging or biochemical tests. • Supports early detection and continuous monitoring of disease progression. • Utilizes Surface Enhanced Raman Spectroscopy to improve sensitivity and specificity.
Applications: • Clinical diagnosis of Alzheimer’s disease in healthcare settings. • Screening tool for early detection in at-risk populations. • Monitoring disease progression in diagnosed patients for personalized treatment planning. • Research tool for studying biochemical changes related to neurodegenerative diseases. • Supportive technology in developing new Alzheimer’s therapies by tracking biochemical responses.
Intellectual Property Summary: Issued patent 9,891,108
Stage of Development: TRL 4
Licensing Status: This technology is available for licensing.